Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "GYNECOLOGIC ONCOLOGY"

Add to list
- Journal Article
- A1
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer

Adriaan Vanderstichele, Liselore Loverix, Pieter Busschaert, Els Van Nieuwenhuysen, Sileny N. Han, Nicole Concin, Tiene Callewaert, Siel Olbrecht, Rawand Salihi (UGent) , Patrick Berteloot, et al.

(2022) GYNECOLOGIC ONCOLOGY. 165(1). p.14-22
Add to list
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer : analysis of the phase III SOLO2/ENGOT-Ov21 study

F. Trillsch, S. Mahner, B. Ataseven, R. Asher, N. Aryal, C. Dubot, A. Clamp, R. Penson, A. Oza, A. Amit, et al.

(2022) GYNECOLOGIC ONCOLOGY. 165(1). p.40-48
Add to list
Clear cell carcinoma of the endometrium

Giorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, Natalie Y.L. Ngoi, Philippe Morice, Takayuki Enomoto, Kazuhiro Takehara, Hannelore Denys (UGent) , Domenica Lorusso, Robert Coleman, et al.

(2022) GYNECOLOGIC ONCOLOGY. 164(3). p.658-666
Add to list
- Journal Article
- A1
Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria

Jolien Haesen, Rawand Salihi (UGent) , Toon Van Gorp, Els Van Nieuwenhuysen, Sileny N. Han, Melissa Christiaens, Anne-Sophie Van Rompuy, Lise Waumans, Patrick Neven and Ignace Vergote

(2021) GYNECOLOGIC ONCOLOGY. 162(3). p.539-545
Add to list
- Journal Article
- A1
- open access
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

S. W. Vrede, W. J. van Weelden, N. C. M. Visser, J. Bulten, L. J. M. van der Putten, Koen Van de Vijver (UGent) , M. Santacana, E. Colas, A. Gil-Moreno, C. P. Moiola, et al.

(2021) GYNECOLOGIC ONCOLOGY. 161(3). p.787-794
Add to list
- Journal Article
- A1
- open access
Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer : a systematic review

Eva Hulstaert, Annelien Morlion (UGent) , Keren Levanon, Jo Vandesompele (UGent) and Pieter Mestdagh (UGent)

(2021) GYNECOLOGIC ONCOLOGY. 160(2). p.633-642
Add to list
Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol

Severien Van Keer, Eliana Peeters, Davy Vanden Broeck (UGent) , Philippe De Sutter, Gilbert Donders, Jean Doyen, Wiebren A. A. Tjalma, Steven Weyers (UGent) , Alex Vorsters and Marc Arbyn (UGent)

(2021) GYNECOLOGIC ONCOLOGY. 162(3). p.575-583
Add to list
- Journal Article
- A1
Increased incidence of ovarian cancer in both endometriosis and adenomyopsis

M. Hermens, A.M. Van Altena, J. Bulten, Hubertus van Vliet (UGent) , A.G. Siebers and R.L.M. Bekkers

(2021) GYNECOLOGIC ONCOLOGY. 162(3). p.735-740
Add to list
Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer

Emiel De Jaeghere (UGent) , Frederiek Laloo, Lien Lippens (UGent) , Mieke Van Bockstal (UGent) , Kathia De Man (UGent) , Eline Naert (UGent) , Jo Van Dorpe (UGent) , Koen Van de Vijver (UGent) , Philippe Tummers (UGent) , Amin Makar (UGent) , et al.

(2020) GYNECOLOGIC ONCOLOGY. 159(2). p.335-343
Add to list
The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review

M. Timmermans, O. van der Hel, G.S. Sonke, Koen Van de Vijver (UGent) , M.A. van der Aa and R.F. Kruitwagen

(2019) Gynecologic Oncology. 153(2). p.445-451

Academic Bibliography

Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer : analysis of the phase III SOLO2/ENGOT-Ov21 study

Clear cell carcinoma of the endometrium

Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer : a systematic review

Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol

Increased incidence of ovarian cancer in both endometriosis and adenomyopsis

Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer

The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review

Contents

Support

Contact